Genetic detoxification of pertussis toxin
AssigneeConnaught Laboratories Limited
InventorsMichel H. Klein, Heather A. Boux, Stephen A. Cockle, Sheena M. Loosmore, Gavin R. Zealey
Life of this patent
Estimating the term…
Abstract
A new method is described for the preparation of a safe, immunogenic and efficacious vaccine for protection against the disease pertussis. In development of this vaccine, specific functional sites of pertussis toxin have been identified, and using this information, defined mutant holotoxins have been produced by site directed mutagenesis of the toxin gene. A number of these toxin analogues are detoxified, retain an immunodominant S1 epitope, are immunoganic and are protective in the standard pertussis vaccine potency test in mice.
Claims16
An immunoprotective genetically detoxified mutant of pertussis holotoxin.
A vaccine against Bordetella pertussis, comprising an effective amount of an immunoprotective genetically-detoxified mutant of pertussis holotoxin or a toxoid thereof, and a physiologically-acceptable carrier therefor.
A conjugate vaccine, comprising an effective amount of an active conjugate comprising a genetically-detoxified mutant of pertussis holotoxin covalently bonded to a hapten, polysaccharide or polypeptide to elicit an antibody response to said hapten, polysaccharide or polypeptide.
Dependencies are inferred from the claim text.